Beneficial Effects of Oral Premarin Estrogen Replacement Therapy Assessed by Human Genome Array

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to assess the immunological status of patients using Premarin. Premarin use is associated with an enhanced immune status, and possibly even some anti-cancer effect. The researchers will compare the use of Premarin with those not using hormone replacement therapy (HRT) to track the effects of Premarin in reducing the risk of infection and swelling.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lawson Health Research Institute
• Treatments: Estrogens; Estrogens, Conjugated (USP)

Criteria

Inclusion Criteria:

• Women taking oral Premarin at least for the last month with no urogenital anatomical abnormalities.

• Women not taking HRT for at least one month with no urogenital anatomical abnormalities (controls).

Exclusion Criteria:

• Males.

• Subjects who are not menopausal.

• Less than 35 years of age.

• Subjects with recurrent sexually transmitted disease.

• Subjects with abnormal renal function (serum creatinine >110umol/l, upper limit 90umol/l) or pyelonephritis.

• Subjects receiving prednisone or immunosuppressive drugs,

• Subjects who need to be treated for any urogenital infection or with any antimicrobial therapy.

• Personal history of known or suspected estrogen-dependent neoplasia such as breast or endometrial cancer.

• Undiagnosed abnormal vaginal bleeding.

• Active hepatic dysfunction or disease, especially of the obstructive type.

• Active thrombophlebitis, thrombosis or thromboembolic disorders.

• Endometrial hyperplasia.

• Subjects on anticoagulants, antidiabetic and antihypertensive agents